title: [Treatment of testicular cancer].
abstract: Germ-cell tumours (GCTs) are the most common type of cancer in young men. Since the late 1970s, disseminated GCT have been a paradigm for curable metastatic cancer and metastatic GCTs are highly curable with cisplatin-based chemotherapy followed by surgical resection of residual masses. Patients' prognosis is currently assessed using the International Germ-Cell Consensus Classification (IGCCC) and used to adapt the burden of chemotherapy. Approximately 20% of patients still do not achieve cure after first-line cisplatin-based chemotherapy, and need salvage chemotherapy (high dose or standard dose chemotherapy). Clinical stage I testicular cancer is the most common presentation and different strategies are proposed: adjuvant therapies, surgery or surveillance. During the last three decades, clinical trials and strong international collaborations lead to the development of a consensus in the management of GCTs.
authors: Université Claude-Bernard - Lyon-I, centre Léon-Bérard, département d'oncologie médicale, 28, rue Laënnec, 69008 Lyon, France.
authors: Jean-Pierre
authors: JP
authors: Droz
authors: Université Claude-Bernard - Lyon-I, centre Léon-Bérard, département d'oncologie médicale, 28, rue Laënnec, 69008 Lyon, France.
authors: Helen
authors: H
authors: Boyle
authors: Hôpital Saint-Louis, service d'oncologie médicale, 1, avenue Claude-Vellefaux, 75010 Paris, France.
authors: Stéphane
authors: S
authors: Culine
authors: Gustave-Roussy Cancer Campus, département de médecine oncologique, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
authors: Karim
authors: K
authors: Fizazi
authors: Université Claude-Bernard - Lyon-I, centre Léon-Bérard, département d'oncologie médicale, 28, rue Laënnec, 69008 Lyon, France.
authors: Aude
authors: A
authors: Fléchon
authors: Gustave-Roussy Cancer Campus, département de médecine oncologique, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
authors: Christophe
authors: C
authors: Massard
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D005602:France; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000266:history; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D009373:Neoplasms, Germ Cell and Embryonal / Q000266:history / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D011379:Prognosis; D035583:Rare Diseases / Q000235:genetics / Q000266:history / Q000473:pathology / Q000628:therapy*; D013736:Testicular Neoplasms / Q000235:genetics / Q000266:history / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents
keywords: cisplatin; germ-cell tumor; residual masses; testicular cancer